Neurobehavioral Profiles and Clinical Consequences of MYT1L-Related Neurodevelopmental Disorder: Insights from the Brain Gene Registry.
Granadillo, J. L.; Kaster, L.; Grewal, D.; Schreiber, A.; Abbacchi, A.; Lanzotti, V.; Brain Gene Registry Consortium, ; Gupta, A.; Gurnett, C. A.; Kroll, K. L.; Dougherty, J.
Show abstract
MYT1L-Related Neurodevelopmental Disorder (MYT1L-NDD) is a rare autosomal dominant syndrome characterized by intellectual disability, global developmental delay, autism, and obesity. Despite growing recognition, prospective and systematic clinical phenotyping remains limited. Here, we analyzed data from 20 individuals with MYT1L variants enrolled in the Brain Gene Registry (BGR), a national platform integrating genetic, neurobehavioral, and clinical data. Neurobehavioral assessments were conducted using the Rapid Neurobehavioral Assessment Protocol (RNAP), including virtual adaptations of the Shipley, Developmental Profile-4, ASEBA Child Behavior Checklist, and Vineland-3. Diagnostic and medication data were extracted from structured electronic health records (EHR). MYT1L participants were compared to the broader BGR cohort. Fourteen participants had pathogenic or likely pathogenic MYT1L variants. Individuals with confirmed MYT1L-NDD exhibited significant impairments in nonverbal cognition and adaptive functioning, particularly in motor tasks, communication, and daily living skills. Behavioral assessments revealed elevated rates of ADHD symptoms, behavioral conduct problems, oppositional defiance, and anxiety. EHR data showed frequent diagnoses of developmental delays, speech and language disorders, gastrointestinal problems, and obesity. Medication data indicated common prescription of alpha-2 adrenergic agonists and laxatives. This study provides the first prospective, multi-source characterization of MYT1L-NDD. Findings expand our understanding of MYT1L-NDD phenotypes in a quantitative and systematic manner and underscore the value of registry-based approaches for understanding rare neurodevelopmental disorders. Larger, longitudinal studies are needed to further define MYT1L-NDD natural history and inform clinical care.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- GM1 Gangliosidosis Type II: Results of a 10-Year Prospective Study 93%
- Heterogeneity of comprehensive clinical phenotype and longitudinal adaptive function and correlation with computational predictions of severity of missense genotypes in KIF1A-associated neurological disorder 92%
- The Australian Genomics Mitochondrial Flagship: A National Program Delivering Mitochondrial Diagnoses 91%
Similar papers in this journal
- A recurrent de novo splice site variant involving DNM1 alternative exon 10a causes developmental and epileptic encephalopathy through a dominant-negative mechanism 93%
- Genome Sequencing and Comprehensive Rare Variant Analysis of 465 Families with Neurodevelopmental Disorders 92%
- Bi-allelic loss-of-function variants in PPFIBP1 cause a neurodevelopmental disorder with microcephaly, epilepsy and periventricular calcifications 90%
Similar papers in this journal
- Medical Multimorbidity in Patients with Treatment-Resistant Psychosis and Rare Copy Number Variants: A Retrospective Case Series of 24 Patients 92%
- Research Priorities of Individuals and Families with Sex Chromosome Aneuploidies 91%
- Systematic Description of 3q29 Duplication Syndrome Reveals New Syndromic Phenotypes: Results from the 3q29 Registry 90%
Similar papers in this journal
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.